All In Biotech

Drug Trial Radar · NCT04359680

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection

A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection

Last checked: Nov 20, 2026Latest source record: Jun 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,407 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,407

Actual

Start

May 13, 2020

Primary completion

Apr 7, 2021

Study completion Apr 7, 2021

Sponsor

Lead sponsor
Romark Laboratories L.C.Industry
Sponsor type
Industry
First posted
Apr 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection

Conditions

  • COVID-19
  • Viral Respiratory Illnesses

Interventions

  • NitazoxanideDrug

    Nitazoxanide 600 mg administered orally twice daily for six weeks

  • PlaceboDrug

    Placebo administered orally twice daily for six weeks

  • Vitamin Super B-ComplexDietary supplement

    Vitamin Super B-Complex administered orally twice daily to maintain the blind

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Proportion of Subjects With Symptomatic Laboratory-confirmed COVID-19 Identified After Start of Treatment and Before the End of the 6-week Treatment Period.Time frame: Up to 6 weeks
  2. The Proportion of Subjects With Symptomatic Laboratory-confirmed VRI Identified After the Start of Treatment and Before the End of the 6-week Treatment Period.Time frame: Up to 6 weeks

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • HealthStar Research LLC

    Hot Springs, Arkansas

  • So Cal Clinical Research

    Huntington Beach, California

  • Long Beach Clinical Trials, LLC

    Long Beach, California

  • Meris Clinical Research

    Brandon, Florida

  • Invesclinica US LLC

    Fort Lauderdale, Florida

  • The Chappel Group Research

    Kissimmee, Florida

  • New Horizon Research Center

    Miami, Florida

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida

  • DMI Research

    Pinellas Park, Florida

  • Tampa General Hospital

    Tampa, Florida

  • Chicago Clinical Research Institute, Inc.

    Chicago, Illinois

  • Chicago Medical Research Institute, Inc.

    Chicago, Illinois

  • Quad Clinical Research

    Chicago, Illinois

  • Chicago Medical Research, LLC

    Hazel Crest, Illinois

  • Centex Studies, Inc.

    Lake Charles, Louisiana

  • Vida Clinical Studies

    Dearborn, Michigan

  • Beacom Family Health Connection

    Fremont, Nebraska

  • North Jersey Community Research Initiative

    Newark, New Jersey

  • Integrative Clinical Trials LLC

    Brooklyn, New York

  • The New York Center for Travel and Tropical Medicine

    New York, New York

  • RH Medical Urgent Care Professional PLLC

    The Bronx, New York

  • Centex Studies, Inc.

    Houston, Texas

  • SMS Clinical Research LLC

    Mesquite, Texas

  • LinQ Research LLC

    Pearland, Texas

  • Rio Grande Valley Clinical Research Institute

    Pharr, Texas

  • BFHC Research

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.